Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 887 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: EPOCH II Clear all

Conditions: Septic Shock
Interventions: Hydroxocobalamin, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: HIV-associated Neuropathy, Polyneuropathy
Interventions: SAB378, methadone, SAB placebo, Methadone placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: San Diego, California • Brooklyn, New York • Rochester, New York

Conditions: Multiple Myeloma, Leukemia, Plasma Cell
Interventions: Carfilzomib, Melphalan, Filgrastim; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD), Carnitine Palmitoyltransferase (CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Longchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency, Trifunctional Protein (TFP) Deficiency
Interventions: UX007; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 6 Months and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Chicago, Illinois + 4 more

Conditions: Metastatic Pancreatic Cancer
Interventions: nab-paclitaxel, gemcitabine, placebo, Necuparanib; Drug
Lead sponsor: Momenta Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 34
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 27 more

Conditions: Scleritis
Interventions: Sirolimus; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Radiation Esophagitis, Locally Advanced Lung Carcinoma
Interventions: Esomeprazole 40 mg; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteers
Interventions: USB005 (aclerastide) Ophthalmic Solution, USB005 Ophthalmic Solution Placebo; Drug
Lead sponsor: US Biotest, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Medication Adherence, Acute Coronary Syndrome
Interventions: PST therapy; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Lebrikizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Long Beach, California • McKinney, Texas

Conditions: Melanoma
Interventions: Glycoprotein 100 (GP100): 209-217 (210M), Interleukin-2 (IL-2), Montanide ISA 51, Melanoma antigen recognized by T-cells (MART)-1: 27-35, 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1, melanoma antigen recognized by T-cells (MART)-1: 26-35(27L); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 7 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Craniopharyngioma
Interventions: Radical Surgery or Limited Surgery, Proton Therapy, ^1^8F-fluorodeoxyglucose, ^1^1C-methionine; Procedure · Device · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2031
U.S. locations: 2
States / cities: Jacksonville, Florida • Memphis, Tennessee

Conditions: -Unhealthy Children With a History of Prematurity
Interventions: MEDI-493; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 5 Months to 6 Months
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Infant, Newborn, Hypoxia-Ischemia, Brain
Interventions: Induced hypothermia, Control; Device
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 6 Hours
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 16
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Oral Cancer Directed Therapy, Breast Cancer, Gastrointestinal Cancer, Oral Chemotherapy
Interventions: Active Care Team Alert, Passive Care Team Alert; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Breast Cancer
Interventions: Paclitaxel, Gemcitabine, Avastin; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Healthy
Interventions: Computer-based cognitive training; Behavioral
Lead sponsor: Posit Science Corporation; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Graft vs Host Disease
Interventions: Atorvastatin calcium (Lipitor); Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Pulmonary Hypertension
Interventions: Iloprost PD-6, Iloprost PD-15; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Iowa City, Iowa + 8 more

Conditions: Mesothelioma, Peritoneal Mesothelioma
Interventions: Nivolumab, Ipilimumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Glioblastoma
Interventions: Re-irradiation (RT), Bevacizumab, Nivolumab, Re-resection; Radiation · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 11
States / cities: Hartford, Connecticut • Indianapolis, Indiana • Basking Ridge, New Jersey + 8 more

Conditions: Ulcerative Colitis
Interventions: Vixarelimab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 15
States / cities: Camarillo, California • Los Angeles, California • Mission Hills, California + 12 more

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: Oral Budesonide Suspension (MB-9), Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 11 Years to 40 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 23
States / cities: Phoenix, Arizona • Orange, California • San Diego, California + 17 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Placebo, Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 9
States / cities: Beverly Hills, California • Encino, California • Irvine, California + 6 more

Search by objective public record fields.

A Trial of Vitamin B12 in Septic Shock

Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Sirolimus Injections for Autoimmune Scleritis

Esomeprazole and Radiation Induced Esophagitis

Study of the Safety of USB005 in Healthy Volunteers

Improving Medication Adherence in Post-ACS Patients

A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection

A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)

Whole-Body Cooling for Birth Asphyxia in Term Infants

EHR-embedded OCDT in Breast or GI Cancer

A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer

Blood Neurotrophic Factors in Adults

Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma

Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically